A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms LEAP-007
Sponsors Merck Sharp & Dohme

Most Recent Events

25 May 2024 This trial has been completed in Poland, according to the European Clinical Trials Database record.
14 May 2024 Status changed from active, no longer recruiting to completed.
09 May 2024 This trial has been completed in Estonia (Global end date: 24 Apr 2024).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight